%0 Journal Article
%T Resultados imediatos e seguimento cl¨ªnico dos pacientes submetidos a implante valvar a¨®rtico transcateter
%A Ghandour
%A Mohamad Said
%A Marchini
%A J¨²lio Fl¨¢vio Meirelles
%A Rocha Neto
%A Alfredo Moreira da
%A Erudilho
%A Eduardo
%A Carnieto
%A N¨¢dia Mendon£¿a
%A Silva
%A Bruno Stefani Lelis
%A Bezerra
%A Bruno Veras
%A Barbosa
%A Daniel Oliveira Neto
%A Nascimento
%A Ingrid Olah do
%A Abensur
%A Henry
%A Souza
%A Janu¨¢rio Manoel de
%A Oliveira
%A Marco Ant£¿nio Pra£¿a de
%A Oliveira
%A S¨¦rgio Almeida de
%A Cristov£¿o
%A Salvador Andr¨¦ Bavaresco
%A Mauro
%A Maria Fernanda Zuliani
%A Mangione
%A Jos¨¦ Armando
%J Revista Brasileira de Cardiologia Invasiva
%D 2012
%I Scientific Electronic Library Online
%R 10.1590/S2179-83972012000300008
%X background: one third of the elderly population with symptomatic calcified aortic stenosis cannot undergo surgery due to their high operative risk. the transcatheter aortic-valve implantation (tavi) has emerged as an alternative therapy for this group of patients. methods: all patients submitted to tavi from november 2008 to april 2012 were included in our study. we report the baseline clinical characteristics, procedural data, hospital outcomes and clinical follow-up of this population. definitions were based on the valve academic research consortium criteria. results: tavi was performed in 23 patients, with 79 ¡À 6.7 years of age, and 56% were female. the euroscore was 20.4 ¡À 11.1%. the corevalve£¿ prosthesis was used in 19 patients (82.6%) and the edwards sapientm valve was used in the remaining ones. procedure success rate was 96%. the mean follow-up was 22 ¡À 12.8 months, with 6 deaths (26.1%) in this period, 3 of which were observed in the first 30 days (13%) and other 2 (21.7%) by the end of the first year. one patient had a transient ischemic attack during hospitalization (4.3%), but there were no episodes of stroke or myocardial infarction in the periprocedural period or in the follow-up. the composite safety endpoint at 30 days was observed in 5 patients (21.7%) and the composite efficacy endpoint at 12 months was 78.3%. conclusions: the results of this study demonstrate that tavi is an attractive procedure for the treatment of patients with calcified aortic stenosis and high operative risk.
%K aortic valve stenosis
%K heart valve prosthesis
%K heart valve prosthesis implantation.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S2179-83972012000300008&lng=en&nrm=iso&tlng=en